Crohn's Disease in
the Clinical Setting
About CIMZIA®
Dosing and
Administration
Clinical Trials Overview
Patient Support
Safety Information
Resources
For Patients & Caregivers
Prescribing Information

This site is intended for
US residents.

PRECiSE 1

PRECiSE 1, a randomized, placebo-controlled study in 662 patients, showed that CIMZIA provides improved response in patients with moderate to severe Crohn's disease1

Learn more about:

Reference:

  1. Sandborn WJ, Feagan BG, Stoinov S, et al; for the PRECiSE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;375:228-238.

 

 

 
CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
For more information 1.866.4.CIMZIA
CIMZIA